media – Page 114 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

BBSRC invests £48m in Babraham Institute to advance lifelong health research

The Biotechnology and Biological Sciences Research Council (BBSRC) has invested £48m into the Babraham Institute, following a five-year review, to support core research on the key mechanisms that maintain the health of cells, tissues and organs. Over the next four years, the institute will receive funding to support research across epigenetics, immunology and cell signalling. The life sciences institute focuses on understanding biology in relation to maintaining health, particularly when protecting and maximising good health in the later years of life. From 2024 to 2028, the new BBSRC investment aims to support three strategic research programmes to advance the ability to protect health and counter age-related decline, including cellular response to stress, epigenetic control across the life course, immunity, resilience and repair. In close collaboration with partners across academia, including the BBSRC’s other strategically supported research institutes and companies based on the Babraham Research Campus, the research will be delivered ...
- Source: drugdu
- 106
- May 16, 2024
MIT’s new MRI brain light-detecting technique could support brain cell studies

Engineers from the Massachusetts Institute of Technology (MIT) have developed a new technique using magnetic resonance imaging (MRI) to detect light deep in the brain, which could benefit future studies of the development and communication of brain cells. Published in Nature Biomedical Engineering, the new technique could help researchers explore the inner workings of the brain, such as changes in gene expression, anatomical connections between cells or how cells communicate with each other. Commonly, scientists label cells with bioluminescent proteins that glow to allow them to track the growth of a tumour or measure changes in gene expression that occur as cells differentiate. Known as bioluminescence, the novel technique uses MRI to observe the dilation of a protein in the brain’s blood vessels to pinpoint the source of light. The team came up with a method to transform the blood vessels of the brain into light detectors to find a ...
- Source: drugdu
- 73
- May 16, 2024
Hengrui Pharmaceuticals Innovative Drug SHR-2173 Injection for IgA Nephropathy Indication Approved for Clinical Use

Recently, Hengrui Pharmaceuticals’ subsidiary Guangdong Hengrui Pharmaceuticals Co., Ltd. received the Notice of Approval for Clinical Trial of Drugs approved by the State Drug Administration, approving SHR-2173 Injection, a Class 1 new drug, to carry out clinical trials for IgA nephropathy. At present, there is no similar drug to SHR-2173 on the market or in the clinical development stage at home and abroad. IgA nephropathy is a group of autoimmune glomerulonephritis characterized by IgA deposition in the glomerular mesangial area. Typical clinical manifestations can be seen in microscopic hematuria, and patients have a history of mucosal (e.g., upper respiratory tract, gastrointestinal tract) infections, which is the most common primary glomerulopathies worldwide, and also a major cause of chronic kidney disease (CKD) and renal failure. In China, IgA nephropathy accounts for 45% of primary glomerular diseases in China. There are geographical differences in the incidence of the disease, and the peak ...
- Source: drugdu
- 72
- May 16, 2024
First Patient Dosed in Phase I Clinical Trial of Degu Insulin Liraglutide Injection

Tong Hua Dong Bao Pharmaceutical Co., Ltd (hereinafter referred to as the “Company”) has initiated the Phase I clinical trial in China after receiving the notification of approval for the clinical trial of Degu Insulin Liraglutide Injection from the State Drug Administration and has recently successfully completed the first case of patient dosing. The completion of Phase I clinical trial of Degu Insulin Liraglutide Injection is another significant progress in the development of GLP-1RA compound formulation of insulin analog, which will further enhance the competitiveness of the Company in the field of endocrine therapy. In the future, the Company is expected to accelerate the process of clinical trials and speed up the approval and listing of its products by virtue of its R&D advantages accumulated in the field of diabetes treatment over the years, so as to provide richer and better choices for clinical medication. Degu Insulin Liraglutide Injection has ...
- Source: drugdu
- 79
- May 16, 2024
【EXPERT Q&A】What does the 4-digit number next to the CE mark on medical devices mean?

Drugdu.com expert’s response: The 4-digit number next to the CE mark on medical devices indicates the Notified Body identification number (or Module D number). These digits identify the Notified Body that has certified the device’s quality management system. It signifies the registration number of the certifying body, indicating that it has assessed the quality management system of the medical device and confirmed its compliance with the relevant European Union directive requirements. This number is crucial for tracking the validity of the certification and for regulatory purposes.
- Source: drugdu
- 136
- May 16, 2024
J&J’s Megadyne discontinues pediatric electrode pad after burn reports

Dive Brief Johnson & Johnson’s Megadyne business has discontinued a pediatric electrode pad after receiving reports of patients being burned during procedures where the device was used. The electrode pad is included in a line of products that were part of a Megadyne recall in December. At that time, the J&J unit restricted the use of four products in patients under the age of 12, but it did not change instructions for one device designed for people who weigh 0.8 to 50 pounds. J&J, which announced the recall Friday, is discontinuing the product indicated for use in people weighing up to 50 pounds after tests on the causes of four reported injuries found a combination of factors that could result in burns. Dive Insight Physicians use Megadyne Mega Soft electrode pads to prevent the risk of burns in procedures that use electrosurgical instruments. When the devices are in place, currents ...
- Source: drugdu
- 77
- May 15, 2024
Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues

Breast cancer remains a major cause of cancer-related mortality among women. Breast-conserving surgery (BCS), also known as lumpectomy, is the removal of the cancerous lump and a small margin of surrounding tissue. This procedure is typically advised for women with early-stage breast cancer or small tumors, as it conserves more of the breast tissue compared to a mastectomy. After undergoing BCS, it is critical to verify that all cancerous cells have been removed to decide if additional surgery is necessary. This verification involves a tumor margin assessment, which examines the edges of the excised tissue (tumor margins) to check for residual cancer cells. Conventionally, this assessment entails staining the tissue samples with dyes and inspecting them under a microscope to differentiate between healthy and cancer cells. However, new optical imaging techniques have emerged as quicker alternatives for conducting these assessments. A group of researchers from the United States, including members ...
- Source: drugdu
- 88
- May 15, 2024
FDA Grants Priority Review Biologics License Application to Dupixent Add-On Maintenance for the Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis

Don Tracy, Associate Editor Dupixent has previously been approved for adults with chronic rhinosinusitis with nasal polyposis whose condition is inadequately controlled. Regeneron and Sanofi announced that the FDA has granted Priority Review to their supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment for adolescents aged 12 to 17 years who have chronic rhinosinusitis with nasal polyposis (CRSwNP) and whose condition is inadequately controlled. With the treatment already approved for adults with CRSwNP, the FDA is expected to make a final decision on the sBLA for the expanded indication by September 15, 2024.1 According to the companies, the application is supported by efficacy data from SINUS-24 and SINUS-52, two trials that showed major improvements in nasal congestion/obstruction severity, nasal polyp size, sense of smell, and a reduction in the need for systemic corticosteroids or surgery. In 2019, Regeneron first released the results of both trials, ...
- Source: drugdu
- 83
- May 15, 2024
Understanding Payer Perceptions

Tasmina Hydery, PharmD With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued education and course-setting for all stakeholders in charting the access landscape is paramount. Tasmina Hydery, PharmD, Associate Director, Market Access and Healthcare Consulting, Cencora Headlined by the launch of nine biosimilars for Humira (adalimumab), the biosimilars market landscape in the US has undergone a significant shift in the last 18 months. The rapid pace of progress—including the emergence of pharmacy-benefit biosimilars—reflects the investment in this space and the growth forecasted over the next half-decade, when the market could reach more than $100 billion.1 Driven by a robust pipeline of products in preclinical and clinical development, the biosimilars market is poised to continue its upward growth trajectory and expand into new therapeutic areas; however, challenges remain. The adoption of adalimumab biosimilars, thus far, remains low and underscores some of the challenges biosimilar manufacturers ...
- Source: drugdu
- 77
- May 15, 2024
NHS reduces long waits for cancer care and achieves faster ambulance responses

For the second month in a row, the NHS has met the 28-day faster diagnosis target for cancer The NHS has announced, for the second month in a row, that it has met the 28-day faster diagnosis target for cancer as well as faster ambulance responses to call outs compared to March 2024. The announcement builds on targeted national support for NHS trusts in reducing variation across the country and speeding up diagnosis for patients, while also bringing down the backlog of patients waiting for diagnosis or treatment from the COVID-19 pandemic. New published data has shown that the number of patients waiting more than 62 days for care is now at its lowest ever since the end of April 2020, reducing by almost 20,000 patients since the post-pandemic peak. In addition, almost 77% of people referred or screened received a definitive diagnosis or were all clear within four weeks, ...
- Source: drugdu
- 164
- May 15, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.